過敏性腸症候群 (Japanese Wikipedia)

Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R (2006). “Costs of irritable bowel syndrome in the UK and US”. PharmacoEconomics. 24 (1): 21–37. doi:10.2165/00019053-200624010-00002. PMID 16445300. S2CID 45376327.
Chen, B.; Morales, G.; Jiang, X. (2018). “Prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome: Systematic review and meta-analysis”. Clinical Gastroenterology and Hepatology 16 (10): 1904–1914. doi:10.1016/j.cgh.2018.03.006. PMID 29545173.
Camilleri, Michael (2021). “American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation”. American Journal of Gastroenterology 116 (1): 17–44. doi:10.14309/ajg.0000000000001047. PMID 33332896.
Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P (December 2007). “Guidelines on the irritable bowel syndrome: mechanisms and practical management”. Gut. 56 (12): 1770–98. doi:10.1136/gut.2007.119446. PMC 2095723. PMID 17488783.
Fukudo S (January 2007). “Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation”. Journal of Gastroenterology. 42 (Suppl 17): 48–51. doi:10.1007/s00535-006-1942-7. PMID 17238026. S2CID 26067985.
Taché, Y; Martinez, V; Wang, L; Million, M (2004). “CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome”. British journal of pharmacology (Wiley) 141 (8): 1321–1330. doi:10.1038/sj.bjp.0705760. ISSN 0007-1188. PMC 1574904. PMID 15100165.
Palsson, Olafur S.; Peery, Anne; Seitzberg, Dorthe; Amundsen, Ingvild Dybdrodt; McConnell, Bruce; Simrén, Magnus (2020-12-07). “Human Milk Oligosaccharides Support Normal Bowel Function and Improve Symptoms of Irritable Bowel Syndrome: A Multicenter, Open-Label Trial”. Clinical and Translational Gastroenterology 11 (12): e00276. doi:10.14309/ctg.0000000000000276. ISSN 2155-384X. PMC 7721220. PMID 33512807.
Chey WD, Kurlander J, Eswaran S (March 2015). “Irritable bowel syndrome: a clinical review”. JAMA. 313 (9): 949–58. doi:10.1001/jama.2015.0954. PMID 25734736. S2CID 205062386.
Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Ford AC (September 2014). “The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis”. The American Journal of Gastroenterology. 109 (9): 1367–74. doi:10.1038/ajg.2014.195. PMID 25070054. S2CID 8076372.
Rao SS, Yu S, Fedewa A (June 2015). “Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome”. Alimentary Pharmacology & Therapeutics. 41 (12): 1256–70. doi:10.1111/apt.13167. PMID 25903636. S2CID 27558785.
Mayer EA (April 2008). “Clinical practice. Irritable bowel syndrome”. The New England Journal of Medicine. 358 (16): 1692–9. doi:10.1056/NEJMcp0801447. PMC 3816529. PMID 18420501.
Khan, Zarghuna; Khan, Saad K.; Reyaz, Ibrahim (2023). “Effectiveness of Rifaximin on the Outcomes of Irritable Bowel Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials”. Cureus 15 (9): e44807. doi:10.7759/cureus.44807. PMID 37809182.
伊藤雅隆, 武藤崇「過敏性腸症候群に対する認知・行動療法の展望」『心理臨床科学』第5巻第1号、心理臨床科学編集委員会、2015年12月、83-94頁、doi:10.14988/pa.2017.0000014355、ISSN 2186-4934、NAID 120005708292。
中谷結花, 武藤崇「青年期における過敏性腸症候群へのアクセプタンス&コミットメント・セラピー（ACT）による介入の可能性」『心理臨床科学』第6巻第1号、心理臨床科学編集委員会、2016年12月、29-42頁、doi:10.14988/pa.2017.0000015386、ISSN 2186-4934、NAID 120006224494。
Oka, Priya; Parr, Heather; Barberio, Brigida; Black, Christopher J.; Savarino, Edoardo V.; Ford, Alexander C. (2020). “Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis”. The Lancet Gastroenterology & Hepatology 5 (10): 908–917. doi:10.1016/S2468-1253(20)30217-X. PMID 32702295.

ibsimpact.wordpress.com (Global: low place; Japanese: low place)

New Rome IV Diagnostic Criteria for Irritable Bowel Syndrome（IBS） Will Include Individualized Clinical Profiles

ibsnet.jp (Global: low place; Japanese: low place)

IBSネット"IBSの治療法"

jrc.or.jp (Global: low place; Japanese: 1,213^th place)

fukui-med.jrc.or.jp

過敏性腸症候群（IBS）について

jsge.or.jp (Global: low place; Japanese: low place)

nih.gov (Global: 5^th place; Japanese: 11^th place)

pubmed.ncbi.nlm.nih.gov

Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R (2006). “Costs of irritable bowel syndrome in the UK and US”. PharmacoEconomics. 24 (1): 21–37. doi:10.2165/00019053-200624010-00002. PMID 16445300. S2CID 45376327.
Chen, B.; Morales, G.; Jiang, X. (2018). “Prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome: Systematic review and meta-analysis”. Clinical Gastroenterology and Hepatology 16 (10): 1904–1914. doi:10.1016/j.cgh.2018.03.006. PMID 29545173.
Camilleri, Michael (2021). “American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation”. American Journal of Gastroenterology 116 (1): 17–44. doi:10.14309/ajg.0000000000001047. PMID 33332896.
Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P (December 2007). “Guidelines on the irritable bowel syndrome: mechanisms and practical management”. Gut. 56 (12): 1770–98. doi:10.1136/gut.2007.119446. PMC 2095723. PMID 17488783.
Fukudo S (January 2007). “Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation”. Journal of Gastroenterology. 42 (Suppl 17): 48–51. doi:10.1007/s00535-006-1942-7. PMID 17238026. S2CID 26067985.
Taché, Y; Martinez, V; Wang, L; Million, M (2004). “CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome”. British journal of pharmacology (Wiley) 141 (8): 1321–1330. doi:10.1038/sj.bjp.0705760. ISSN 0007-1188. PMC 1574904. PMID 15100165.
Palsson, Olafur S.; Peery, Anne; Seitzberg, Dorthe; Amundsen, Ingvild Dybdrodt; McConnell, Bruce; Simrén, Magnus (2020-12-07). “Human Milk Oligosaccharides Support Normal Bowel Function and Improve Symptoms of Irritable Bowel Syndrome: A Multicenter, Open-Label Trial”. Clinical and Translational Gastroenterology 11 (12): e00276. doi:10.14309/ctg.0000000000000276. ISSN 2155-384X. PMC 7721220. PMID 33512807.
Chey WD, Kurlander J, Eswaran S (March 2015). “Irritable bowel syndrome: a clinical review”. JAMA. 313 (9): 949–58. doi:10.1001/jama.2015.0954. PMID 25734736. S2CID 205062386.
Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Ford AC (September 2014). “The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis”. The American Journal of Gastroenterology. 109 (9): 1367–74. doi:10.1038/ajg.2014.195. PMID 25070054. S2CID 8076372.
Rao SS, Yu S, Fedewa A (June 2015). “Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome”. Alimentary Pharmacology & Therapeutics. 41 (12): 1256–70. doi:10.1111/apt.13167. PMID 25903636. S2CID 27558785.
Mayer EA (April 2008). “Clinical practice. Irritable bowel syndrome”. The New England Journal of Medicine. 358 (16): 1692–9. doi:10.1056/NEJMcp0801447. PMC 3816529. PMID 18420501.
Khan, Zarghuna; Khan, Saad K.; Reyaz, Ibrahim (2023). “Effectiveness of Rifaximin on the Outcomes of Irritable Bowel Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials”. Cureus 15 (9): e44807. doi:10.7759/cureus.44807. PMID 37809182.
Mozaffari S, Rahimi R, Abdollahi M (2010). “Implications of melatonin therapy in irritable bowel syndrome: a systematic review”. Curr. Pharm. Des. (33): 3646-55. PMID 21128901.
Oka, Priya; Parr, Heather; Barberio, Brigida; Black, Christopher J.; Savarino, Edoardo V.; Ford, Alexander C. (2020). “Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis”. The Lancet Gastroenterology & Hepatology 5 (10): 908–917. doi:10.1016/S2468-1253(20)30217-X. PMID 32702295.

ncbi.nlm.nih.gov

Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P (December 2007). “Guidelines on the irritable bowel syndrome: mechanisms and practical management”. Gut. 56 (12): 1770–98. doi:10.1136/gut.2007.119446. PMC 2095723. PMID 17488783.
Taché, Y; Martinez, V; Wang, L; Million, M (2004). “CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome”. British journal of pharmacology (Wiley) 141 (8): 1321–1330. doi:10.1038/sj.bjp.0705760. ISSN 0007-1188. PMC 1574904. PMID 15100165.
Palsson, Olafur S.; Peery, Anne; Seitzberg, Dorthe; Amundsen, Ingvild Dybdrodt; McConnell, Bruce; Simrén, Magnus (2020-12-07). “Human Milk Oligosaccharides Support Normal Bowel Function and Improve Symptoms of Irritable Bowel Syndrome: A Multicenter, Open-Label Trial”. Clinical and Translational Gastroenterology 11 (12): e00276. doi:10.14309/ctg.0000000000000276. ISSN 2155-384X. PMC 7721220. PMID 33512807.
Mayer EA (April 2008). “Clinical practice. Irritable bowel syndrome”. The New England Journal of Medicine. 358 (16): 1692–9. doi:10.1056/NEJMcp0801447. PMC 3816529. PMID 18420501.

niddk.nih.gov

“Definition and Facts for Irritable Bowel Syndrome”. NIDDKD (2015年2月23日). 2016年4月2日時点のオリジナルよりアーカイブ。2016年3月29日閲覧。
“Symptoms and Causes of Irritable Bowel Syndrome”. NIDDK (2015年2月23日). 2017年3月2日時点のオリジナルよりアーカイブ。2016年3月29日閲覧。
“Treatment for Irritable Bowel Syndrome”. NIDDK (2015年2月23日). 2016年3月29日閲覧。

pmc.ncbi.nlm.nih.gov

Taché, Y; Martinez, V; Wang, L; Million, M (2004). “CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome”. British journal of pharmacology (Wiley) 141 (8): 1321–1330. doi:10.1038/sj.bjp.0705760. ISSN 0007-1188. PMC 1574904. PMID 15100165.
Palsson, Olafur S.; Peery, Anne; Seitzberg, Dorthe; Amundsen, Ingvild Dybdrodt; McConnell, Bruce; Simrén, Magnus (2020-12-07). “Human Milk Oligosaccharides Support Normal Bowel Function and Improve Symptoms of Irritable Bowel Syndrome: A Multicenter, Open-Label Trial”. Clinical and Translational Gastroenterology 11 (12): e00276. doi:10.14309/ctg.0000000000000276. ISSN 2155-384X. PMC 7721220. PMID 33512807.

nii.ac.jp (Global: 195^th place; Japanese: 15^th place)

ci.nii.ac.jp

牛若博文、「排便スケールを作成して統一した排便記録をつける」『新田塚医療福祉センター雑誌』 5巻 1号、p.21 - 23、2008-08-30、NAID 120001339385
伊藤雅隆, 武藤崇「過敏性腸症候群に対する認知・行動療法の展望」『心理臨床科学』第5巻第1号、心理臨床科学編集委員会、2015年12月、83-94頁、doi:10.14988/pa.2017.0000014355、ISSN 2186-4934、NAID 120005708292。
中谷結花, 武藤崇「青年期における過敏性腸症候群へのアクセプタンス&コミットメント・セラピー（ACT）による介入の可能性」『心理臨床科学』第6巻第1号、心理臨床科学編集委員会、2016年12月、29-42頁、doi:10.14988/pa.2017.0000015386、ISSN 2186-4934、NAID 120006224494。

nikkeibp.co.jp (Global: 1,879^th place; Japanese: 122^nd place)

medical.nikkeibp.co.jp

日経メディカル - 【新薬】リナクロチド（リンゼス）新規作用機序の便秘型過敏性腸症候群治療薬 2017/4/14 北村正樹（東京慈恵会医科大学附属病院薬剤部）
ポリアクリル樹脂経口薬（過敏性腸症候群治療薬）解説日経メディカル処方薬事典
5-HT3受容体拮抗薬（過敏性腸症候群治療薬）解説日経メディカル処方薬事典
リナクロチド（過敏性腸症候群治療薬）解説日経メディカル処方薬事典
過敏性腸症候群用薬、2位のトリメブチンがシェア伸長：日経メディカル

okochi-cl.com (Global: low place; Japanese: low place)

過敏性腸症候群における漢方薬の使い分け (PDF)

semanticscholar.org (Global: 15^th place; Japanese: 750^th place)

api.semanticscholar.org

Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R (2006). “Costs of irritable bowel syndrome in the UK and US”. PharmacoEconomics. 24 (1): 21–37. doi:10.2165/00019053-200624010-00002. PMID 16445300. S2CID 45376327.
Fukudo S (January 2007). “Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation”. Journal of Gastroenterology. 42 (Suppl 17): 48–51. doi:10.1007/s00535-006-1942-7. PMID 17238026. S2CID 26067985.
Chey WD, Kurlander J, Eswaran S (March 2015). “Irritable bowel syndrome: a clinical review”. JAMA. 313 (9): 949–58. doi:10.1001/jama.2015.0954. PMID 25734736. S2CID 205062386.
Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Ford AC (September 2014). “The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis”. The American Journal of Gastroenterology. 109 (9): 1367–74. doi:10.1038/ajg.2014.195. PMID 25070054. S2CID 8076372.
Rao SS, Yu S, Fedewa A (June 2015). “Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome”. Alimentary Pharmacology & Therapeutics. 41 (12): 1256–70. doi:10.1111/apt.13167. PMID 25903636. S2CID 27558785.

u-fukui.ac.jp (Global: low place; Japanese: 8,608^th place)

karin21.flib.u-fukui.ac.jp

牛若博文、「排便スケールを作成して統一した排便記録をつける」『新田塚医療福祉センター雑誌』 5巻 1号、p.21 - 23、2008-08-30、NAID 120001339385

umin.jp (Global: low place; Japanese: 1,501^st place)

neuro-g.umin.jp

本郷道夫、RomeIIIを日本語で解釈する日本神経消化器病学会] (PDF)

web.archive.org (Global: 1^st place; Japanese: 1^st place)

“Definition and Facts for Irritable Bowel Syndrome”. NIDDKD (2015年2月23日). 2016年4月2日時点のオリジナルよりアーカイブ。2016年3月29日閲覧。
“Symptoms and Causes of Irritable Bowel Syndrome”. NIDDK (2015年2月23日). 2017年3月2日時点のオリジナルよりアーカイブ。2016年3月29日閲覧。

worldcat.org (Global: 4^th place; Japanese: 12^th place)

search.worldcat.org

Taché, Y; Martinez, V; Wang, L; Million, M (2004). “CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome”. British journal of pharmacology (Wiley) 141 (8): 1321–1330. doi:10.1038/sj.bjp.0705760. ISSN 0007-1188. PMC 1574904. PMID 15100165.
Palsson, Olafur S.; Peery, Anne; Seitzberg, Dorthe; Amundsen, Ingvild Dybdrodt; McConnell, Bruce; Simrén, Magnus (2020-12-07). “Human Milk Oligosaccharides Support Normal Bowel Function and Improve Symptoms of Irritable Bowel Syndrome: A Multicenter, Open-Label Trial”. Clinical and Translational Gastroenterology 11 (12): e00276. doi:10.14309/ctg.0000000000000276. ISSN 2155-384X. PMC 7721220. PMID 33512807.
伊藤雅隆, 武藤崇「過敏性腸症候群に対する認知・行動療法の展望」『心理臨床科学』第5巻第1号、心理臨床科学編集委員会、2015年12月、83-94頁、doi:10.14988/pa.2017.0000014355、ISSN 2186-4934、NAID 120005708292。
中谷結花, 武藤崇「青年期における過敏性腸症候群へのアクセプタンス&コミットメント・セラピー（ACT）による介入の可能性」『心理臨床科学』第6巻第1号、心理臨床科学編集委員会、2016年12月、29-42頁、doi:10.14988/pa.2017.0000015386、ISSN 2186-4934、NAID 120006224494。

過敏性腸症候群 (Japanese Wikipedia)

cghjournal.org (Global: low place; Japanese: low place)

doi.org (Global: 2nd place; Japanese: 3rd place)

ibsimpact.wordpress.com (Global: low place; Japanese: low place)

ibsnet.jp (Global: low place; Japanese: low place)

jrc.or.jp (Global: low place; Japanese: 1,213th place)

fukui-med.jrc.or.jp

jsge.or.jp (Global: low place; Japanese: low place)

nih.gov (Global: 5th place; Japanese: 11th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

niddk.nih.gov

pmc.ncbi.nlm.nih.gov

nii.ac.jp (Global: 195th place; Japanese: 15th place)

ci.nii.ac.jp

nikkeibp.co.jp (Global: 1,879th place; Japanese: 122nd place)

medical.nikkeibp.co.jp

okochi-cl.com (Global: low place; Japanese: low place)

semanticscholar.org (Global: 15th place; Japanese: 750th place)

api.semanticscholar.org

u-fukui.ac.jp (Global: low place; Japanese: 8,608th place)

karin21.flib.u-fukui.ac.jp

umin.jp (Global: low place; Japanese: 1,501st place)

neuro-g.umin.jp

web.archive.org (Global: 1st place; Japanese: 1st place)

worldcat.org (Global: 4th place; Japanese: 12th place)

search.worldcat.org

doi.org (Global: 2^nd place; Japanese: 3^rd place)

jrc.or.jp (Global: low place; Japanese: 1,213^th place)

nih.gov (Global: 5^th place; Japanese: 11^th place)

nii.ac.jp (Global: 195^th place; Japanese: 15^th place)

nikkeibp.co.jp (Global: 1,879^th place; Japanese: 122^nd place)

semanticscholar.org (Global: 15^th place; Japanese: 750^th place)

u-fukui.ac.jp (Global: low place; Japanese: 8,608^th place)

umin.jp (Global: low place; Japanese: 1,501^st place)

web.archive.org (Global: 1^st place; Japanese: 1^st place)

worldcat.org (Global: 4^th place; Japanese: 12^th place)